1050 nm Optical Coherence Tomography of Choroidal Melanocytic Lesions

Published: 27-04-2009 Last updated: 05-05-2024

To evaluate the use of the new generation OCT in detecting retinal and choroidal changes associated with pigmented tumors of the choroid; in particular, transformations of benign lesions into malignant melanomas.

Ethical review Approved WMO **Status** Recruiting

Health condition type Ocular neoplasms

Study type Observational non invasive

Summary

ID

NL-OMON33058

Source

ToetsingOnline

Brief title

SDOCT & melanomas.

Condition

Ocular neoplasms

Synonym

melanoma, neoplasma, tumor

Research involving

Human

Sponsors and support

Primary sponsor: Oogziekenhuis Rotterdam

Source(s) of monetary or material Support: Stichting Wetenschappelijk Onderzoek

Oogziekenhuis Prof. Dr. H.J. Flieringa (SWOO)

Intervention

Keyword: choroidal nevus, melanoma, SDOCT

Outcome measures

Primary outcome

Correlation of conventional diagnostics and 1050 nm OCT imaging.

Secondary outcome

- Ophthalmic examination outcome: benign or malignant aspect of lesion.
- Presence of lipofuscin indicates malignancy.
- Autofluorescence outcome: hyperautofluorescence indicates malignancy .
- Ultrasonography: thickness and diameter of the lesion

Study description

Background summary

Prevalence of melanocytic choroidal lesions is about 20% in the Caucasian population. Differentiation between small malignant melanoma and choroidal nevus is rather difficult. Possibly, OCT can detect early stages of transformation of choroidal nevi into malignant melanomas.

Study objective

To evaluate the use of the new generation OCT in detecting retinal and choroidal changes associated with pigmented tumors of the choroid; in particular, transformations of benign lesions into malignant melanomas.

Study design

Observational cross-sectional and longitudinal cohort-study.

Study burden and risks

Patients in this study do not benefit and receive no financial compensation. There are no anticipated major side effects. Study related measurements occur in combination with regular clinical visits and will take about 40 minutes per visit. There will be 3 visits in 1 year. Total study time is 2 hours. Burden is considered to be low.

Contacts

Public

Oogziekenhuis Rotterdam

Schiedamse Vest 180 3011 BH Rotterdam NL

Scientific

Oogziekenhuis Rotterdam

Schiedamse Vest 180 3011 BH Rotterdam NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

- Age >= 18 years.
- Informed consent.
- Choroidal melanocytic lesion.

Exclusion criteria

- Media opacities preventing imaging.
- Use of systemic or dermatological infrared-photosensitive medication.

Study design

Design

Study type: Observational non invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

Recruitment

NL

Recruitment status: Recruiting
Start date (anticipated): 04-04-2010

Enrollment: 20

Type: Actual

Ethics review

Approved WMO

Date: 27-04-2009

Application type: First submission

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam

(Rotterdam)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

4 - 1050 nm Optical Coherence Tomography of Choroidal Melanocytic Lesions 9-05-2025

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

CCMO NL26968.078.09